Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Biomedica ; 32(1): 13-22, 2012.
Article in Spanish | MEDLINE | ID: mdl-23235783

ABSTRACT

INTRODUCTION: Damage of testicles is frequent in lepromatous leprosy and worsened by the presence of erythema nodosum leprosum. Objective. A patient is presented who developed lepromatous leprosy and erythema nodosum leprosum with major testicular compromise. MATERIAL AND METHODS: The 28-year-old male patient had lepromatous leprosy since age 22. During a polychemotherapy treatment for the lepromatous leprosy, he presented chronic erythema nodosum leprosum that affected both testicles; he did not respond to the conventional treatment. A left orchidectomy was performed to treat the persistent pain. RESULTS: The extracted testis evidenced the following: tubular atrophy, extensive fibrosis, cumulus of foamy macrophages without rods, focal Leydig cell hyperplasia, linfocitary and granulomatous arteritis and endarteritis of small and medium size vessels. These changes were also observed in the epididymis. Two years after the polychemoterapy and the orchidectomy, the patient exhibited azoospermy, normal total testosterone, slightly diminished free testosterone and elevated levels of luteinizing hormone and follicle-stimulating hormone. No loss of libido or sexual activity was reported. General concepts of erythema nodosum leprosum were reviewed, as well as the pathologic changes produced by leprosy in the testis. CONCLUSION: Lepromatous leprosy may lead to hypogonadism. This condition is recommended for inclusion in leprosy diagnostic programs in order to detect and treat the consequences of the possible hypogonadism.


Subject(s)
Erythema Nodosum/etiology , Hypogonadism/etiology , Leprosy, Lepromatous/complications , Testicular Diseases/etiology , Adult , Atrophy , Azoospermia/etiology , Clofazimine/therapeutic use , Dapsone/therapeutic use , Epididymis/pathology , Erythema Nodosum/pathology , Erythema Nodosum/surgery , Fibrosis , Foam Cells/pathology , Follicle Stimulating Hormone/blood , Humans , Hyperplasia , Hypogonadism/blood , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/classification , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/immunology , Leprosy, Lepromatous/pathology , Leydig Cells/pathology , Luteinizing Hormone/blood , Male , Orchiectomy , Rifampin/therapeutic use , Testicular Diseases/pathology , Testicular Diseases/surgery , Testosterone/blood , Thalidomide/therapeutic use
2.
Biomédica (Bogotá) ; 32(1): 13-22, ene.-mar. 2012. ilus, tab
Article in Spanish | LILACS | ID: lil-639807

ABSTRACT

Introducción. La afección testicular es frecuente en la lepra lepromatosa, daño que se incrementa cuando cursa con eritema nudoso leproso. Objetivo. Presentar un paciente con lepra lepromatosa y eritema nudoso leproso con grave compromiso testicular. Materiales y métodos. Se estudió un hombre de 28 años con lepra lepromatosa desde los 22, que durante la poliquimioterapia para la lepra presentó eritema nudoso leproso crónico que afectó ambos testículos y no respondió al manejo convencional. El dolor persistente obligó a practicar orquidectomía izquierda. Resultados. Este testículo presentaba atrofia tubular y fibrosis notorias, conglomerados de macrófagos espumosos, sin bacilos, hiperplasia focal de células de Leydig, endarteritis y arteritis linfocitaria y granulomatosa de vasos pequeños y medianos; estos cambios también estaban presentes en el epidídimo. Un estudio llevado a cabo dos años después de terminar su tratamiento y de la orquidectomía izquierda, demostró azoospermia, testosterona total normal, testosterona libre discretamente disminuida y hormonas lutropina (luteinizante) y folitropina (estimulante del folículo) elevadas. No había disminución de la libido ni de su actividad sexual. Se revisaron los conceptos generales sobre el eritema nudoso leproso y las alteraciones que la lepra produce en el testículo. Conclusión. La lepra lepromatosa puede conducir a hipogonadismo. Los programas de lepra deben contemplar esta complicación para corregir y evitar sus secuelas.


Introduction. Damage of testicles is frequent in lepromatous leprosy and worsened by the presence of erythema nodosum leprosum. Objective. A patient is presented who developed lepromatous leprosy and erythema nodosum leprosum with major testicular compromise. Material and methods. The 28-year-old male patient had lepromatous leprosy since age 22. During a polychemotherapy treatment for the lepromatous leprosy, he presented chronic erythema nodosum leprosum that affected both testicles; he did not respond to the conventional treatment. A left orchidectomy was performed to treat the persistent pain. Results. The extracted testis evidenced the following: tubular atrophy, extensive fibrosis, cumulus of foamy macrophages without rods, focal Leydig cell hyperplasia, linfocitary and granulomatous arteritis and endarteritis of small and medium size vessels. These changes were also observed in the epididymis. Two years after the polychemoterapy and the orchidectomy, the patient exhibited azoospermy, normal total testosterone, slightly diminished free testosterone and elevated levels of luteinizing hormone and follicle-stimulating hormone. No loss of libido or sexual activity was reported. General concepts of erythema nodosum leprosum were reviewed, as well as the pathologic changes produced by leprosy in the testis. Conclusion. Lepromatous leprosy may lead to hypogonadism. This condition is recommended for inclusion in leprosy diagnostic programs in order to detect and treat the consequences of the possible hypogonadism.


Subject(s)
Adult , Humans , Male , Erythema Nodosum/etiology , Hypogonadism/etiology , Leprosy, Lepromatous/complications , Testicular Diseases/etiology , Atrophy , Azoospermia/etiology , Clofazimine/therapeutic use , Dapsone/therapeutic use , Epididymis/pathology , Erythema Nodosum/pathology , Erythema Nodosum/surgery , Fibrosis , Foam Cells/pathology , Follicle Stimulating Hormone/blood , Hyperplasia , Hypogonadism/blood , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/classification , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/immunology , Leprosy, Lepromatous/pathology , Leydig Cells/pathology , Luteinizing Hormone/blood , Orchiectomy , Rifampin/therapeutic use , Testicular Diseases/pathology , Testicular Diseases/surgery , Testosterone/blood , Thalidomide/therapeutic use
3.
J Commun Dis ; 37(3): 219-25, 2005 Sep.
Article in English | MEDLINE | ID: mdl-17080706

ABSTRACT

Hypogonadism in male patients with Leprosy is common and may identify patients with future risk for bone loss and osteoporosis. In the present study, we evaluated gonadal function in 71 male patients with Leprosy both clinically and by estimation of serum testosterone levels. The patients belonged to selected rural areas of Uttar pradesh, with majority aged less than 50 yrs (74.6%), Hindus (66.7%), illiterate (60.9%), and of low socioeconomic status (58% with per capita income < Rs.500 per month). Most patients had multibacillary Leprosy (83.1%), duration less than 2 years (75.4%) and had received antileprosy drugs for less than a year (95.6 %). Seven patients (9.9%) had clinical features of hypogonadism such as gynaecomastia, decreased sexual hair and infertility. Serum testosterone levels, estimated in 31 of the patients, revealed low values in 25.8% (8/31) patients (Mean 4.65+/-3.37 ng/ml). Age, duration of Leprosy and socioeconomic status but not type of Leprosy or treatment duration affected hypogonadism significantly. The results of the present study indicate a high frequency of hypogonadism among rural male Leprosy patients that warrants routine screening to identify patients at risk for osteoporosis and possible prevention with testosterone replacement therapy.


Subject(s)
Hypogonadism/complications , Leprosy/epidemiology , Testosterone/blood , Adolescent , Adult , Humans , Hypogonadism/blood , India/epidemiology , Leprostatic Agents/administration & dosage , Leprosy/blood , Leprosy/complications , Leprosy/drug therapy , Male , Middle Aged , Risk Factors , Rural Health , Socioeconomic Factors
4.
Lepr Rev ; 60(2): 94-101, 1989 Jun.
Article in English | MEDLINE | ID: mdl-2505006

ABSTRACT

Luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone levels were determined by radioimmunoassay (RIA) in leprosy patients and analysed for effect of disease classification, disease activity and duration of disease. LH and FSH levels were found to be significantly elevated in lepromatous patients compared to borderline-lepromatous, midborderline and borderline-tuberculoid patients. A positive correlation was seen between LH and FSH and a negative correlation was seen between testosterone and both LH and FSH. No correlation was seen between hormone levels and measures of disease activity: bacillary index and IgM to phenolic glycolipid I, a Mycobacterium leprae antigen. A significant correlation was seen between duration of disease and FSH when age was taken into account, indicating that testicular dysfunction is probably cumulative and irreversible. It is recommended that LL patients be routinely screened for hypogonadism using FSH, LH and testosterone levels.


Subject(s)
Follicle Stimulating Hormone/blood , Hypogonadism/blood , Leprosy/blood , Luteinizing Hormone/blood , Testosterone/blood , Humans , Hypogonadism/etiology , Leprosy/classification , Leprosy/complications , Male , Random Allocation
5.
Horm Metab Res ; 16(3): 146-50, 1984 Mar.
Article in English | MEDLINE | ID: mdl-6425184

ABSTRACT

Pituitary testicular functions were evaluated in leprosy. Forty-three men with leprosy were studied by basal estimations of plasma LH, FSH, Prolactin, Testosterone, 17-beta estradiol, metoclopramide stimulated prolactin responses and hCG stimulated testosterone responses. Fifteen young healthy men with proven fertility were studied as control subjects. The hormone estimations were related to the histologic changes observed in the testicular biopsies of leprous hypogonadism. In lepromatous leprosy (n:18) the basal plasma gonadotropin levels were significantly increased (FSH 29.5 +/- 2.3 mlU/ml; LH 21.5 +/- 1.9 mlU/ml, mean +/- SE). The plasma gonadotropins were in the normal range in tuberculoid leprosy. In borderline leprosy, the basal mean plasma FSH was normal, whereas LH levels were significantly increased (22.5 +/- 1.2 mlU/ml). The basal plasma testosterone levels were significantly decreased in lepromatous leprosy (1.6 +/- 0.12 ng/ml), tuberculoid leprosy (4.2 +/- 1.7 ng/ml) and borderline leprosy (1.8 +/- 0.18 ng/ml). The basal plasma 17-beta estradiol levels were significantly elevated in all the three types of leprosy. The basal plasma prolactin levels in plasma were significantly increased in lepromatous and tuberculoid leprosy. During hCG stimulation tests, the peak plasma testosterone responses were significantly reduced in both lepromatous leprosy and tuberculoid leprosy subjects. The blunted testosterone responses during hCG stimulation tests in leprosy correlated with the high basal 17-beta estradiol levels (r = 0.58; P less than 0.05). These results strongly suggest that hypogonadism in leprosy results from primary testicular failure. The significant elevation of plasma 17-beta estradiol levels in lepromatous, tuberculoid and borderline leprosy could play a role in hypogonadism of leprosy.


Subject(s)
Hormones/blood , Hypogonadism/blood , Leprosy/blood , Testis/pathology , Adult , Chorionic Gonadotropin , Estradiol/blood , Follicle Stimulating Hormone/blood , Humans , Hypogonadism/etiology , Leprosy/complications , Leprosy/pathology , Luteinizing Hormone/blood , Male , Metoclopramide , Middle Aged , Prolactin/blood , Testosterone/blood
SELECTION OF CITATIONS
SEARCH DETAIL